- Min.Order :1 Gram
- Purity: 98%
- Payment Terms : L/C
Keywords
13-((dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2H)-dione Arxxant LY 333531
Quick Details
- Appearance:Solid powder
- Application:Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-maximal inhibitory constant of 4.5 and
- PackAge:inquiry
- ProductionCapacity:10|Kilogram|Month
- Storage:
- Transportation:inquiry
Superiority:
Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-maximal inhibitory constant of 4.5 and 5.9 n M , respectively. The half-life of ruboxistaurin, which can be orally administered, is approximately 9 h and that of its metabolite 16 h, therefore allowing once-daily dosing. Based on data from clinicalTrials.gov, Children's Hospital Medical Center, Cincinnati plan a phase I/II trial of the effect of ruboxistaurin for its safety, tolerability, and effectiveness in treating adult patients with heart failure on June 9, 2016.#
Details:
You Might Also Like
Related Searches
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View